FENNEC PHARMACEUTICALS INC's ticker is FENC and the CUSIP is 31447P100.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,040 | +99.7% | 1,470 | +134.8% | 0.00% | – |
Q2 2023 | $5,527 | +21157.7% | 626 | -79.9% | 0.00% | -100.0% |
Q1 2023 | $26 | -10.3% | 3,118 | +0.8% | 0.00% | 0.0% |
Q4 2022 | $29 | -99.9% | 3,092 | -14.4% | 0.00% | – |
Q3 2022 | $29,000 | +26.1% | 3,611 | -9.2% | 0.00% | -100.0% |
Q2 2022 | $23,000 | +2200.0% | 3,977 | +2781.9% | 0.00% | – |
Q1 2022 | $1,000 | -96.2% | 138 | -97.7% | 0.00% | – |
Q4 2021 | $26,000 | -16.1% | 5,970 | +17.6% | 0.00% | -100.0% |
Q1 2021 | $31,000 | -13.9% | 5,075 | +4.2% | 0.00% | 0.0% |
Q4 2020 | $36,000 | -71.4% | 4,870 | -76.6% | 0.00% | 0.0% |
Q3 2020 | $126,000 | +1160.0% | 20,807 | +1669.3% | 0.00% | – |
Q2 2020 | $10,000 | +42.9% | 1,176 | +1.1% | 0.00% | -100.0% |
Q4 2019 | $7,000 | +250.0% | 1,163 | +183.7% | 0.00% | – |
Q3 2019 | $2,000 | -88.2% | 410 | -88.3% | 0.00% | -100.0% |
Q1 2019 | $17,000 | +466.7% | 3,512 | +1029.3% | 0.00% | – |
Q3 2018 | $3,000 | +200.0% | 311 | +279.3% | 0.00% | – |
Q1 2018 | $1,000 | -92.9% | 82 | -92.5% | 0.00% | -100.0% |
Q4 2017 | $14,000 | +250.0% | 1,091 | +172.8% | 0.00% | – |
Q3 2017 | $4,000 | – | 400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Solas Capital Management, LLC | 849,979 | $3,400,000 | 3.47% |
Southpoint Capital Advisors LP | 3,997,214 | $15,989,000 | 0.60% |
Opaleye Management Inc. | 295,000 | $1,180,000 | 0.36% |
683 Capital Management, LLC | 971,351 | $3,885,000 | 0.35% |
Avoro Capital Advisors LLC | 1,105,999 | $4,424,000 | 0.15% |
Eventide Asset Management | 720,000 | $2,880,000 | 0.09% |
Granahan Investment Management | 439,083 | $1,756,000 | 0.09% |
Hartford Financial Management Inc. | 20,300 | $81,000 | 0.03% |
OXFORD ASSET MANAGEMENT LLP | 75,236 | $301,000 | 0.01% |
Paloma Partners Management Co | 54,400 | $218,000 | 0.00% |